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1. Introduction
Genetic disorders caused primarily by abnormalities in genes or chromosomes are rare in the
general population. The associated putative mutations that lead to a high risk of developing
such diseases are even rarer. In order to study disease risks associated with mutated genes,
families sampled under different study designs are commonly used in association studies.
This is because family data recruited via affected individuals (probands) would be expected
to contain more affected individuals and mutation carriers than families randomly sampled
from a general population, thus leading to increased statistical efficiency in estimating the
disease risk. The disease risk associated with a mutated gene can be measured on a relative or
absolute scale. As the event we consider is disease with its age of onset, the relative risk can
be measured as a ratio of two hazards of developing disease between mutation carriers and
non-carriers, and the absolute risk as a function of age, i.e., the cumulative risk of developing
disease by a given age, which is also termed penetrance.
Several family-based study designs have been used for estimating the disease risk associated
with a gene mutation when onset varies with age. Gong & Whittemore (2003) discussed two
basic types of family-based sampling schemes: population-based and clinic-based designs.
For population-based designs, families are ascertained for study inclusion based on affected
family members who are randomly sampled from the disease population. The proband is
usually genotyped to determine if s/he carries the disease risk gene and additional genotype
and phenotype data can then be collected from other family members. A kin-cohort design
described by Wacholder et al. (1998) is an example of the population-based design as
families are sampled through a volunteer (either affected or unaffected) who agrees to be
genotyped and provides the disease history of her or his first-degree relatives through a
questionnaire. Not restricted to including the first degree relatives and genotyping only
probands, a kin-cohort design can be easily extended to case-family studies to include more
extended family members and their genotype information. Case-control family studies have
been widely used to analyse the ages of onset of disease in relation to genetic risk (Li et al.,
1998; Shih & Chatterjee, 2000; Hsu & Gorfine, 2006), where case families are recruited via
population-based cases and their matching control families are randomly sampled from the
population.
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For clinic-based designs, on the other hand, families are ascertained into the study based on
having multiple affected family members in addition to the affected probands. Pedigrees
with many cases are highly informative because they are more likely to carry the disease
gene mutation, but typically have not been ascertained in any population-based manner.
Such families are often identified from high-risk disease clinics and provide substantial
information to estimate the disease risk (for example, Kopciuk et al., 2009). Multistage designs
(Whittemore & Halpern, 1997; Siegmund et al., 1999) provide an alternative way to efficiently
recruit high risk families, often using disease family registries, where families are sampled
from more informative groups via several stages. Studies based on these high-risk families
can be effective for characterizing the prevalence and penetrance of mutated genes, but it is
well known that without proper ascertainment corrections statistical inference would lead
to biased estimations of population attributes such as allele frequency, disease risks, and
penetrance of the mutated genes.
To allow population-based inference for estimating disease risks associated with mutated
genes, family data can be analyzed using various likelihood-based methods (Thomas, 2004).
In particular, ascertainment-corrected likelihood approaches have been developed by several
authors (for example, Choi et al., 2008; Carayol & Bonaïti-Pellié, 2004; Kraft & Thomas, 2000;
Le Bihan et al., 1995). Based on the survival approach, Le Bihan et al. (1995) formulated a
prospective likelihood for modeling phenotypes as the age of onset and disease status given
genotypes, and corrected the likelihood by the probability of families being ascertained for
study. This approach is natural as it models phenotypes as a function of genotype and
covariates, but the ascertainment scheme has to be clearly known and simple enough to
make proper correction. On the other hand, the retrospective likelihood models genotypes
conditioning on the phenotypes of all family members (Carayol & Bonaïti-Pellié, 2004; Kraft
& Thomas, 2000; Schaid et al., 2010). Although this approach provides the most robust
way to obtain consistent estimates of relative risk even with the ascertainment schemes that
are imprecisely defined or complex, it encounters the computational burden of summing
over possible genotypes of all family members and a decreased efficiency resulting from
conditioning. Choi et al. (2008) adapted the retrospective likelihood conditioning only
on phenotypes of individuals who were involved in the ascertainment criteria; for families
sampled from the population-based designs, only probands were used to correct for the
ascertainment, whereas for families from the clinic-based designs, the probands and their
parents and sibs were used for ascertainment correction. Moreover, Schaid et al. (2010)
accommodated the composite likelihood approach to obtaining the retrospective likelihood
based on all possible pairs of individuals in families to reduce the computational burden.
The main objectives of this article are first, to examine the effects of misspecification of study
designs when more appropriate study designs have been ignored or incorrectly specified in
the analysis; second, to provide simple and easy to apply adjustment schemes for estimating
disease risks by combining family data from different study designs; and third, to develop an
Expectation-Maximization algorithm to infer missing genotypes in the estimation of disease
risks. We start with describing ascertainment-corrected likelihood methods to take the study
design into account and propose a likelihood-based approach to estimating the disease risks
for combined family data collected under different study designs. The performance of
these ascertainment-corrected likelihood methods is evaluated in terms of bias and efficiency.
The effect of design misspecification is examined for estimating the disease risks associated
with mutated genes. The bias and efficiency involved in estimating two disease risks are
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compared when only probands for the families from the clinic-based study are adjusted
for, and when the probands and other affected family members for the families from the
population-based design are used for ascertainment correction. For the combined family
data, the two design correction methods (population-based and clinic-based) are applied
and compared respectively with our proposed combined likelihood method in terms of their
accuracies and efficiencies for disease risk estimation.
This chapter includes the following sections. Section 2 introduces two family-based study
designs—the population- and clinic-based study designs and their ascertainment-corrected
likelihood methods for modeling ages at onset for family members in disease risk estimation.
We propose a likelihood-based approach for the combined family data obtained from different
study designs. In Section 3, an Expectation-Maximization (EM) algorithm is incorporated
to account for the missing genotype information, where the missing genetic covariates are
inferred from their conditional expectation given the observed genotypes and phenotypes of
other family members. Moreover, a robust variance estimator is proposed to account for the
dependence of individuals within families. Using simulation studies in Section 4, we examine
the effects of study design misspecification for estimating the disease risks and investigate the
properties of our proposed likelihood approach for combined families from different study
designs. In Section 5, we illustrate our proposed approaches through an application to family
data obtained from the combination of two studies of Lynch Syndrome—first, Newfoundland
data from the clinic-based design and second, Ontario data based on the population-based
design. Final remarks and possible extensions of this work will follow in Section 6.
2. Methods
2.1 Defining disease risks
For diseases caused by mutated genes, the phenotype of interest varies in age at onset, i.e.,
time to an event such as death or disease diagnosis. We denote the age at onset by T, the
affection status at age of examination by δ. Then, the phenotype is given by D = (T, δ).
Under the Cox’s proportional hazards model, the hazard function for individual i conditional
on mutation gene G and other risk factors X is assumed to take the form
h(ti|gi,xi) = ho(t) exp(βgG + βxX),
where ho(t) is a baseline hazard function and βg and βx are unknown regression parameters.
Based on this model, we consider two types of disease risk associated with a mutated
gene—relative risk and absolute risk, the latter is also called penetrance.
(1) the relative risk in survival analysis is defined by the hazards ratio for an individual with
a mutated gene compared to an individual free from the mutation, that is
Relative Risk = exp(βg).
(2) the penetrance function for the disease susceptibility gene is defined as the age-specific
cumulative risk function conditional on the disease susceptibility gene G and other relevant
covariates X,
Penetrance = P(T < t|G,X) .
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Design Ascertainment Criteria
POP Proband is affected
POP+ Proband is affected and mutation-carrier
CLI Proband is affected and at least one parent and one sib are affected
CLI+ Proband is affected mutation-carrier and at least one parent and
one sibling are affected
Table 1. Family-based study designs
The disease risks can be estimated by maximizing a likelihood function with proper
ascertainment adjustment of the families. In a crude analysis of family data, their
ascertainments are often corrected by simply excluding the probands from the analysis to
prevent overestimating the risk. However, more prudent approaches such as likelihood
methods would not simply drop out the probands because they include other important
information about the disease risks. Rather they would adjust for the sampling process,
allowing their contributions to the likelihood. To accommodate study designs and the
ascertainment process properly, both the design and the ascertainment criteria should be
known clearly. However, such designs or criteria in many cases are unclear or too complex
to allow adjustment at the analysis stage. Moreover, family data could come from different
sources where families were recruited using different designs or ascertainment criteria.
2.2 Family-based study designs
We consider the two most commonly used family-based study designs—population-based
designs and clinic-based designs. The population-based study design uses the affected
cases (probands) to sample their families while the clinic-based study design is based on
the probands with a high family history of disease risk. Thus, the clinic-based families
likely include more disease cases and mutation carriers compared to the families from
population-based designs.
The ascertainment criteria for the population-based study are based on the affected probands
who are randomly sampled from the diseased population; for example, cancer registries.
To increase the power to study the effect of the mutated gene of interest, one can apply
stringent criteria to recruit the probands to be not only affected but also be a mutation-carrier.
Similarly, the clinic-based study designs can have two variants: one with random probands
with multiple case family members and the other with carrier probands with multiple case
family members. Such families can be recruited from cancer registries or cancer clinics.
Table 1 summarizes the four study designs and their sampling criteria used to ascertain
families. Population-based designs correspond to ascertainment criteria POP and POP+.
They are similar to a kin-cohort design but are more like case-family designs that include
extended family members and their genotype information. Ascertainment criteria CLI and
CLI+ correspond to clinic-based designs which have multiple disease occurrences among
family members. Important to note is that ascertainment criteria for the POP+ and CLI+
designs include families who have at least one member (proband) who carries the mutated
gene of interest.
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2.3 Likelihood approaches for family-based study designs
This section describes the likelihood-based approaches for modeling ages at onset and genetic
covariates using family data via population-based and clinic-based study designs. We propose
a combined likelihood approach for family data arising from the two different study designs.
2.3.1 Ascertainment-corrected retrospective likelihood
The retrospective likelihood corrects for the ascertainment by conditioning on the phenotypes.
Define D = (d1, . . . , dn) as a vector of phenotypes, G = (g1, . . . , gn) as a vector of genotypes,
X = (x1, . . . , xn) a vector of covariates other than genotypes, and A the ascertainment event.
The likelihood contribution L f for a single family f can be written as
L f = P(G f |D f ,X f , A f )
=
P(A f |D f ,X f ,G f )P(D f |X f ,G f )P(G f )
P(D f , A f |X f )
∝
P(D f |X f ,G f )P(G f )
P(D f , A f |X f )
, (1)
where we assume that P(A f |D f ,X f ,G f ) is equal to 1 if the vector D f qualifies for
ascertainment, and 0 otherwise, and so is independent of the parameter of interest.
We further assume that individuals’ phenotypes are independent conditionally given their
genotypes and covariates. Thus, we can express the numerator as
P(D f |X f ,G f ) =
n f
∏
i=1
P(di|xi, gi) ,
and
P(G f ) =
n f
∏
i=1
{
P(gi), if individual i is a founder,
P(gi|gmi , g fi ), if individual i is a nonfounder.
Here P(gi) is based on Hardy-Weinberg Equilibrium (HWE) and depends on the population
allele frequency, P(gi|gmi , g fi ) is the Mendelian transmission probability given parents’
genotypes (gmi , g fi ) of individual i.
The denominator is the correction term used to account for the study designs. In the
population-based study, the ascertainment correction is based on the proband’s phenotype
in that it equals the probability of the proband, p, being affected before his/her age at
examination, ap, i.e.,
P(D f , A f |X f ) = ∑
g
P(Tp < ap|g)P(g),
where the sum is over all possible genotypes of the proband. For POP+ design, the sum takes
place by assuming the proband is a mutation carrier.
In the clinic-based study, the denominator is based on the phenotypes of four individuals,
two parents and two sibs, who involved in their family’s ascertainment process. It can be
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expressed as
P(D f , A f |X f ) = ∑
Gω
P(Tf < a f |x f , gω f )
δ f P(Tf ≥ a f |x f , gω f )
1−δ f ×
P(Tm < am|xm, gωm )
δm P(Tm ≥ am|xm, gωm )
1−δm P(gω f , gωm |gωp )×
P(Ts < as|xs, gωs )P(gωs |gωp )P(Tp < ap|xp, gωp )P(gωp ),
where indices f ,m, s, p represent father, mother, sib and proband, respectively, δ indicates the
affection status, and Gω = (gω f , gωm , gωp , gωs ) includes all possible genotypes of the four
individuals in the ascertainment set. For CLI+ design, the sum in the denominator is taken
over all possible genotypes, provided that the proband carries a mutated allele of the major
gene. The conditional probabilities P(gω f , gωm |gωp = 1) and P(gωs |gωp = 1) are obtained
based on the HWE and Mendelian transmission probabilities using Bayes theorem.
2.3.2 Combined population- and and clinic-based study designs
Consider a study where the families are sampled via different study designs, say np families
from a population-based design and nc families from a clinic-based design. When their study
designs are known, we can construct the likelihoods based on their study designs. Let Lp and
Lc be the likelihood functions based on the population-based design and clinic-based design,
respectively. We propose the combined likelihood for the families from the two designs as
Lcomb(θ|D,G,X) = Lp(θ|D
p,Gp,Xp)Lc(θ|D
c,Gc,Xc),
where the superscripts p and c denote the population- and clinic-based study designs,
respectively, and the likelihoods Lp and Lc are obtained using the retrospective likelihood
approach in expression (1). Therefore, the combined likelihood using the retrospective
likelihood approach can accommodate both population- and clinic-based designs.
Even when the sampling schemes are not clearly defined, we can still employ this combined
likelihood approach by dividing the families into two groups—high risk and low risk families,
according to the number of cases observed in the family. For example, a family would be
classified as a high risk family if it includes at least three cases among family members,
otherwise it would be classified as a low risk family.
3. Missing genotypes
In practice, family data often include some missing information, particularly, missing
genotypes. In the presence of missing genotype information, we estimate the disease risks
associated with a known gene mutation in the families. Suppose data include genetic
covariates that consist of observed genotypes and missing genotypes and phenotypes as
time-of-onset responses with no missing. To infer the unobserved genotypes in the family, we
implement an expectation-maximazation (EM) algorithm (Dempster et al., 1977) and estimate
the parameters in the likelihood. The EM algorithm is an iterative procedure that computes
the maximum likelihood estimates (MLEs) in the presence of missing data.
3.1 Expectation-maximazation algorithm
Suppose a genetic covariate G f in family f consists of observed genotypes G f o and missing
genotypes G f m and the vector of unknown parameters θ includes both regression parameters
384 Epidemiology Insights
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and baseline hazard parameters. In our situation, the expectation of the complete data
(D f ,X f ,G f ), f = 1, . . . , n, is taken with respect to the conditional distribution of missing
genotypes G f m given observed data (D f ,X f ,G f o) and current estimates of θ. Then the
parameter estimates are updated by maximizing the likelihood function using the estimate
of missing data in the expectation step. These two steps iterate until convergence to obtain the
MLEs, where the algorithm is guaranteed to increase the likelihood at each iteration.
The conditional expectation of the log-likelihood function ℓ(θ|D,G,X) of the complete data
(D,G,X) given the observed phenotypes Do and genotypes Go, or Q function for the kth
iteration is given by:
Q(θ|θ(k)) = Eθ(k) [ℓ(θ|D,G,X)|Do,Go] . (2)
For the ith individual in family f , we can then obtain the conditional expectation of their
missing genotype Gi given their observed phenotype Di, covariates Xi, and the observed
mutation status Go of other family members, especially if the proband’s genotype Gp is
conditioned as:
Eθ(k) [Gi|Di,Xi,Gp = 1] = Pθ(k) (Gi|Di,Xi,Gp = 1)
=
Pθ(k) (Di|Xi,Gi)P(Gi|Gp = 1)
Pθ(k) (Di|Xi,Gi = 1)P(Gi = 1|Gp = 1) + Pθ(k) (Di|Xi,Gi = 0)P(Gi = 0|Gp = 1)
.
Here P(Gi|Gp = 1) is the conditional probability of the mutation carrier status for family
member i, using the family proband’s known mutation status. Based on Mendelian
transmission probabilities, we can express these as simple constants under an assumed genetic
model. Under the model assumptions given above, the phenotype probabilities conditional
on genotype status for the ith individual can be expressed in terms of the hazard function h
and the corresponding survival function S depending on his/her affection status δi as
P(Di|Xi,Gi) = S(ti;Xi,Gi)h(ti;Xi,Gi)
δi .
In the M step of the algorithm, we take the partial derivatives of Q with respect to θ and set
to zero, that will maximize Q.
3.2 Robust variance estimator for the EM algorithm
We illustrate the use of robust variance estimators (sandwich estimators) to account for
within-family dependencies for disease risk estimates. In the presence of missing genotypes,
the variance estimators are modified accordingly upon the use of the EM algorithm (Louis,
1982).
Let U(θ) and B(θ) denote the score vector and the negative of the associated matrix of second
derivatives for the complete data, respectively, and U∗(θ) and B∗(θ) be the corresponding
vector and matrix for the incomplete data. Then, the observed information matrix can be
expressed as
Io(θ) = Eθ [B(θ)|go, do]− Eθ [U(θ)U
⊤(θ)|go, do] + U
∗(θ)U∗⊤(θ), (3)
where go and do denote the vectors of observed genotypes and phenotypes from data. At
the maximum likelihood estimate of θ, because of the convergence of the EM algorithm, U∗
385On Combining Family Data from Different Study Designs for Estimating Diseas  Risk Associated with Mutated G nes
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is zero. Thus, the observed information matrix can be obtained as the first two terms on the
right hand side of (3) that arise from the complete data log-likelihood analysis. The first term
is evaluated as
Eθ [B(θ)|go, do] = Eθ
[
−
∂2ℓ(θ)
∂θ∂θ⊤
|go, do
]
.
Oakes (1999) explicitly expressed the information matrix in terms of derivatives of the
Q(θ|θ(k)) function in equation (2) invoked by the EM algorithm, as given by
Io(θ) =
∂2ℓ
∂θ∂θ⊤
=
{
∂2Q(θ|θ(k))
∂θ∂θ⊤
+
∂2Q(θ|θ(k))
∂θ∂θ(k)⊤
}
θ=θ(k)
, (4)
where ℓ represents the observed data log-likelihood and the second term is viewed as the
‘missing information.’
To account for familial correlation, as our model assumes the independence of the individuals
in the family, we obtain the robust variance estimator for the ascertainment corrected
likelihood with missing genotypes in a ‘sandwich’ form (White, 1982),
Var(θˆ) = Io(θ)
−1
⎧⎨
⎩
n
∑
f=1
U∗f (θ)U
∗
f (θ)
⊤
⎫⎬
 Io(θ)−1, (5)
where U∗f (θ) is the conditional expectation of the complete data score vector for family f
given the observed data. Thus, the robust variance of θˆ can be estimated by replacing θ by θˆ
in equation (5).
4. Simulation study
We carried out simulation studies to investigate the properties of our proposed likelihood
methods and the effect of design misspecification. The simulation study aims to (1) assess bias
and efficiency in disease risk estimation (relative risk and penetrance) for the retrospective
likelihood-based approaches for family data from different study designs, (2) investigate
potential bias and efficiency loss in risk estimation when the study designs are misspecified,
and (3) evaluate the first two aims using combined data from two different study designs.
4.1 Family data generation
The simulation of family data is based on the method developed by Gauderman (1995) and
further extended by Choi et al. (2008). We generated families of three generations: two parents
and their two offspring, one of whom is the proband (affected individual from whom the
family is selected). Each offspring has a spouse and their children ranged in number from
two to five. At the first stage, all family members’ ages at examination were obtained using a
normal distribution withmean age 65 for the first generation and 45 for the second generation,
with variance fixed at 2.5 years for both generations. It resulted in an average of 20 years
difference between the parents and offspring. At the next stage, the proband’s genotype of a
major gene was determined conditioning on the proband’s affection status by her/his age at
examination, assuming Hardy-Weinberg equilibrium (HWE) with the fixed population allele
frequency. Given the proband’s genotypes, the genotypes of the other family members were
then determined using HWE andMendelian transmission probabilities calculated with Bayes’
386 Epidemiology Insights
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formula. Once we simulated the age at examination and genotype information for all family
members, then the time-to-onset of individual i was simulated from the proportional hazards
model,
h(ti|gi) = h0(ti) exp(βxi),
where xi indicates a carrier status of disease mutation gene for subject i and the baseline
hazard is assumed to follow the Weibull distribution which has a form, h0(t) = λρ{λ(t −
20)}ρ−1.
The proband’s age at onset was generated conditioning on the fact that the proband was
affected before his(her) age at examination, ap,
Tp ∼ T|T < ap .
For the rest of family members, their times to onset were generated unconditionally. We also
assumed the minimum age at onset was 20 years of age and the maximum age for followup
was 90 years of age. Finally, the affection status δi for the ith individual was determined by
comparing the age at onset Ti and age at examination ai; δi = 1 if Ti < ai and 0 otherwise.
4.2 Simulation study designs
Data were simulated under different configurations. We assumed Weibull baseline hazard
functions with scale (λ) and shape (ρ) parameters equal to 0.01 and 3.2, respectively. This
leads to a cumulative risk of 10% among mutation non-carriers by age 70. Two penetrances
were considered: high and low penetrances corresponding to the log relative risk of a major
gene (β) given by 2.4 and 1.8, respectively. The high penetrance represents a lifetime risk
of 70% by age 70 among carriers of a major gene, which assumes a rare gene with the allele
frequency 0.02 under the dominant model. The low penetrance provides a lifetime risk of 48%
by age 70 among carriers.
We designed the simulation studies, first to investigate the effect of design misspecification,
and second, to examine the properties of our proposed likelihood for combined family data
from different study designs in the estimation of disease risks associated with a mutated gene.
(1) To study the effect of design misspecification, the study designs POP, POP+, CLI, and CLI+
were used to generate family data. For each design, two retrospective likelihood methods
were applied to fit the data—one using correct adjustment of the study design and the other
using a design with misspecified correction; for example, population-based ascertainment
correction was used for the families under CLI+ design and clinic-based ascertainment
correction was used for the families under POP+ design as for the misspecified design. We
simulated 500 random samples of 200 families for each simulation configuration.
(2) To investigate potential bias and efficiency loss in disease risk estimation for the proposed
likelihood approach for combined family data from population-based and clinic-based
designs. We considered the combined families either from POP+ and CLI+ designs or POP
and CLI designs with three mixing ratios between two designs—50-50, 70-30 and 80-20. For
example, with the total 400 families sampled, the ratio 50-50 corresponds to equal numbers
of families from POP+ and CLI+ designs, the 70-30 sampling corresponds to 280 POP+
families and 120 CLI+ families and the ratio 80-20 to 320 POP+ and 80 CLI+ families. The
same numbers were examined for combining POP and CLI families. For each simulation
configuration, 500 random samples were simulated.
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4.3 Simulation results
Results of the simulation studies are described based on the empirical summary measures of
bias and standard error obtained from the maximum likelihood estimates.
4.3.1 The effect of design misspecification
We first assessed bias and precision in disease risk estimation (relative risk and penetrance)
for the retrospective likelihood with correct design adjustment for family data from different
study designs. The results are summarized in Table 2.
With the correct design adjustment, the estimates of both the log relative risk and penetrance
appeared unbiased; the absolute values of bias were less than 0.05 under both high and
low penetrance models regardless of the study design. The magnitude of the bias was
much smaller than the standard errors. In the log relative risk estimation, the precision
of clinic-based designs was higher (smaller standard errors) than that of population-based
designs. The population-based designs provided more accurate and precise estimates of the
log relative risk for high penetrance than for low penetrance, whereas the clinic-based designs
performed better for low penetrance. However, in the penetrance estimation, all designs
provided more precise penetrance estimates (smaller standard errors) for high penetrance
than for low penetrance.
We then examined the effect of design misspecification in terms of bias and precision of the
log relative risk and penetrance estimates obtained from the retrospective likelihoods when
the study design was misspecified. The clinic-based ascertainment correction was applied to
the family data under the population-based designs and the population-based ascertainment
correction to the clinic-based study. It is worth noting that the clinic-based design with the
population-based correction provided relatively large bias in both disease risks, however, the
bias in the population-based design with the clinic-based ascertainment correction was not
notably large. Especially, under POP+ design (with affected and mutation carrier probands),
the clinic-based retrospective likelihood yielded estimates at least as accurate as those from
probands-only adjustment (correct design), although their standard errors were larger under
the misspecified design.
4.3.2 The likelihood methods for combined family data from different study designs
We evaluated the accuracy and precision of the disease risk (log relative risk and penetrance)
estimates based on the three retrospective likelihoods for combined data. Simulation results
based on the combined data from CLI+ and POP+ designs are summarized in Table 3, and
those from combining CLI and POP families in Table 4 .
Combined data from POP+ and CLI+ designs
In the log relative risk estimation, as expected, the population-based likelihoods for the
combined data yielded overestimates because the ascertainment correction was based on only
probands, which would not be sufficient for the families from clinic-based designs. However,
the clinic-based retrospective likelihood provided slightly negative but less biased estimates
in log relative risk but slightly larger standard errors. Although the population-based
likelihoods provided smallest standard errors, they were subject to positive bias. Moreover,
the log relative risk estimates for low penetrance performed better (less bias and higher
precision) than for high penetrance. Our proposed likelihood was almost as efficient as the
388 Epidemiology Insights
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Log relative risk (β) estimation
High Penetrance (β = 2.4) Low Penetrance (β = 1.8)
POP POP+ CLI CLI+ POP POP+ CLI CLI+
Correct -0.002 0.010 0.044 -0.015 -0.006 0.017 0.017 -0.003
Design (0.129) (0.236) (0.095) (0.171) (0.153) (0.256) (0.066) (0.136)
Misspecified 0.033 -0.022 1.456 0.444 0.041 0.009 0.665 0.475
Design (0.159) (0.265) (0.201) (0.165) ( 0.185) (0.272) (0.151) (0.144)
Penetrance estimation
High Penetrance (70%) Low Penetrance (48%)
POP POP+ CLI CLI+ POP POP+ CLI CLI+
Correct 0.013 0.015 0.028 0.020 0.008 0.012 0.049 0.037
Design (0.049) (0.033) (0.078) (0.084) (0.057) (0.040) (0.115) (0.103)
Misspecified 0.034 0.009 0.290 0.282 0.056 0.014 0.501 0.480
Design (0.087) (0.098) (0.003) (0.004) (0.140) (0.135) (0.003) (0.006)
Table 2. Effects of the design misspecification: bias and precision in disease risk estimation
based on retrospective likelihoods with correct and incorrect design adjustments; standard
errors are in parenthesis.
population-based likelihood and as accurate as the clinic-based likelihood, regardless of the
mixing rates we considered. Especially, the combined likelihood appeared to perform better
for relative risk estimation when more CLI+ families were included in the sample.
In the penetrance estimation, we observed similar patterns as in the log relative risk
estimation. The population-based likelihood provided substantially large bias with small
standard errors, whereas the clinic-based likelihood yielded less bias with large standard
errors. However, our proposed likelihood method offered the least bias and improved
precision compared to the clinic-based likelihood. In addition, the penetrance was more
precisely estimated with the combined likelihood when fewer CLI+ families were recruited
(20% CLI+ families).
Combined data from POP and CLI designs
The patterns of bias and precision of the three likelihood methods were more clear with the
combined data from POP and CLI designs, as shown in Table 4. In the log relative risk
estimation, our proposed likelihood yielded both the most accurate and precise estimates.
It also provided more precise estimates when 50% CLI families were included. Similarly, in
penetrance estimation, the population-based likelihood provided heavily biased estimates;
however, the combined likelihood performed well in terms of both bias and precision. With
fewer CLI families (20%) in the data, more precise estimates were obtained.
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Log relative risk (β) estimation
High Penetrance (β = 2.4) Low Penetrance (β = 1.8)
POP+ vs. CLI+ 50-50 70-30 80-20 50-50 70-30 80-20
POP+ corrected 0.279 0.196 0.145 0.326 0.240 0.191
likelihood (0.132) (0.142) (0.149) (0.123) (0.139) (0.145)
CLI+ corrected -0.024 -0.024 -0.026 -0.004 -0.010 -0.002
likelihood (0.140) (0.154) (0.163) (0.124) (0.141) (0.150)
Combined -0.025 -0.026 -0.028 -0.005 -0.011 -0.005
likelihood (0.134) (0.143) (0.149) (0.123) (0.140) (0.147)
Penetrance estimation
High Penetrance (70%) Low Penetrance (48%)
POP+ vs. CLI+ 50-50 70-30 80-20 50-50 70-30 80-20
POP+ corrected 0.209 0.151 0.113 0.348 0.247 0.182
likelihood (0.009) (0.015) (0.017) (0.012) (0.017) (0.020)
CLI+ corrected 0.019 0.016 0.015 0.032 0.021 0.024
likelihood (0.060) (0.067) (0.067) (0.079) (0.083) (0.085)
Combined -0.008 -0.011 -0.012 0.002 -0.002 -0.002
likelihood (0.031) (0.029) (0.027) (0.033) (0.030) (0.028)
Table 3. Bias and precision in disease risk estimation based on three retrospective likelihood
approaches for combined data from different family based designs (POP+ and CLI+) with
affected and mutation carrier probands; standard errors are in parenthesis.
5. Application to Lynch Syndrome families
Lynch Syndrome, also referred to as hereditary non-polyposis colorectal cancer is an
autosomal dominant condition which predisposes carriers to colorectal cancer (CRC). Several
DNA mismatch repair (MMR) genes responsible for the majority of Lynch Syndrome cancers
have been identified, predominantly MLH1 and MSH2. For the study of CRC, Lynch
Syndrome families share a founder mutation in an MMR gene sampled from Newfoundland
and Ontario. The Newfoundland data consist of 315 phenotyped individuals (74 affected and
241 not affected) from 12 very large families identified using a high risk criteria. Of them, 261
were genotyped (162 carriers, 99 non-carriers) and 54 were not genotyped. Each family had
a carrier proband and other affected relatives, which corresponds to the study design CLI+.
The Ontario data were identified through the Ontario Familial Colorectal Cancer Registry
(Cotterchio et al., 2000) and consist of 506 phenotyped individuals (126 affected and 380 not
affected) from 32 families with MMR mutation carrier probands, which corresponds to the
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Log relative risk (β) estimation
High Penetrance (β = 2.4) Low Penetrance (β = 1.8)
POP vs. CLI 50-50 70-30 80-20 50-50 70-30 80-20
POP corrected 0.911 0.644 0.485 0.700 0.609 0.506
likelihood (0.089) (0.079) (0.078) (0.094) (0.089) (0.089)
CLI corrected 0.044 0.035 0.038 0.020 0.024 0.029
likelihood (0.079) (0.086) (0.094) (0.063) (0.077) (0.087)
Combined 0.014 -0.009 -0.017 0.003 0.000 -0.002
likelihood (0.072) (0.076) (0.080) (0.058) (0.068) (0.076)
Penetrance estimation
High Penetrance (70%) Low Penetrance (48%)
POP vs. CLI 50-50 70-30 80-20 50-50 70-30 80-20
POP corrected 0.269 0.237 0.203 0.467 0.413 0.353
likelihood (0.005) (0.010) (0.013) (0.007) (0.012) (0.018)
CLI corrected 0.043 0.041 0.042 0.059 0.060 0.062
likelihood (0.055) (0.055) (0.056) (0.081) (0.082) (0.082)
Combined 0.006 -0.002 -0.005 0.015 0.008 0.006
likelihood (0.042) (0.038) (0.036) (0.047) (0.043) (0.042)
Table 4. Bias and precision in disease risk estimation based on three retrospective likelihood
approaches for combined data from different family based designs (POP and CLI) with
random affected probands; standard errors are in parenthesis.
study design POP+. Of them, 154 individuals were genotyped (92 carriers, 62 non-carriers)
and 352 were not genotyped.
The three likelihood methods (POP+ corrected, CLI+ corrected and combined likelihoods)
were applied to combined families with Lynch Syndrome identified from Newfoundland
(CLI+) and Ontario (POP+). A Weibull model was used to assess the effects of MMR
mutation gene and gender on the age at onset of colorectal cancer. The EM algorithm was
implemented to infer missing genotypes. The results of fitting these Lynch Syndrome families
using different likelihood methods are presented in Table 5, and the age-specific penetrance
estimates based on the combined likelihood are graphically illustrated in Figure 1.
In the analysis based on the combined likelihood, the β parameters for the genetic and gender
effects were estimated to be 1.13 with robust standard error (se) = 0.18 and -0.51 with se=0.17,
respectively, which lead to the hazards ratio of the MMR mutation carriers for the colorectal
cancer as 3.10 (se=0.55) and the hazards ratio between female and male as 0.60 (se=0.11).
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Fig. 1. (a) Estimated cumulative risk of developing colorectal cancer for carriers of any MMR
gene mutation for the Lynch Syndrome families from Newfoundland and Ontario. (b) Same
as (a) for non-carriers.
Log relative risk estimation in terms of hazards ratio
MMRmutation Gender
POP+ corrected likelihood 1.07 (0.17) -0.42 (0.16)
CLI+ corrected likelihood 1.15 (0.18) -0.52 (0.18)
Combined likelihood 1.14 (0.18) -0.51 (0.17)
Age-specific penetrance estimation among mutation carriers
Male Female
POP+ corrected likelihood 62.4% (4.08) 47.5% (4.06)
CLI+ corrected likelihood 58.9% (4.27) 40.9% (4.18)
Combined likelihood 60.7% (4.15) 42.8% (4.10)
Table 5. Disease risk estimates and their corresponding robust standard errors in parenthesis
using different likelihood methods for the Lynch Syndrome families from Newfoundland
and Ontario
These relative risks indicated that the MMRmutation carriers were approximately three times
more likely to develop the colorectal cancers than non-carriers, whereas among males and
females, females showed about one third lower the hazard rate than males. There was very
little difference observed between the relative risk estimates obtained by the CLI+ corrected
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likelihood and the combined likelihood, although their precisions were slightly better with
the combined likelihood.
We obtained that the penetrance of colorectal cancer by age 70 was 61% (se=4.15) among
male carriers and 43% (se=4.1) among female carriers using the combined likelihood.
These estimates were comparable with those obtained using the POP+ and CLI+ corrected
retrospective likelihoods. Penetrances were overestimated (62% for male and 48% for female
carriers) with higher precision (se=4.08 for male, 4.06 for female) under POP+ correction
but slightly underestimated (59% for male carriers and 41% for female carriers) with lower
precision (se=4.27 for male and 4.18 for female) under CLI+ correction, as seen in our
simulation study.
6. Conclusion
In genetic epidemiology, family studies have been widely used for identifying genes
responsible for traits and characterizing their risks in the population and they are often based
on various family-based designs to sample families depending on the objectives of the study
or their budget. To make population-based inferences, the study design should be properly
taken into account, especially when the sampling is not randomly conducted as often is the
case with the sampling of families.
In this study, for estimating disease risks—relative risk and penetrance, we have proposed
the use of a retrospective likelihood to take the sampling process of families into account,
and investigated the effect of sampling design misspecification on disease risk estimation.
Our study showed that the misspecification of study design undoubtedly lead to bias;
overestimation of risks when the study design adjustment was less than it should be
(i.e, the clinic-based designs were analyzed with the correction by probands only), and
underestimation with overcorrection by multiple affected family members. However, the
magnitudes of bias and precision varied depending on the study design and the size of
the penetrance. We found that undercorrection created more bias although it provided
smaller standard error. This implies that conditioning more individuals would be safer
for obtaining accurate estimates at the price of loss of precision if the study design is not
known. The POP+ design with clinic-based correction in fact provided unbiased estimates
of relative risk and penetrance. In general, the population-based designs performed better
for high penetrance for estimating both disease risks but the clinic-based designs performed
differently: penetrance was more efficiently estimated under high penetrance but relative
risk was more efficiently estimated under low penetrance. In addition, we have proposed
the combined likelihood for families sampled under different study designs and the effect of
design misspecification was also investigated for combined data. Our proposed likelihood is
applicable even when the study designs of the combined data are not clearly known since
we can divide families into two categories—high risk families with at least three affected
individuals and low risk families, otherwise. Our proposed combined retrospective likelihood
method yielded accurate and precise estimates of both disease risks. Comparatively, the
clinic-based likelihoods applied to combined data and provided unbiased estimates less
efficiently compared to those from the combined likelihood. It is noteworthy that the EM
algorithmwe developed for inferring missing genotypes is a novel way to impute the missing
genotypes using the observed genotypic and phenotypic information from other family
members.
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In practice, it might be difficult to collect families with a mutation-carrier proband. However,
with the emergence of large international consortiums such as the Breast and Colon Cancer
Family Registries, the planning of studies using designs POP+ and CLI+ is now quite feasible.
Therefore, the use of 200 families in the CLI+ design, as specified in our simulation study,
seems to provide a reasonable sample size; however, the efficiency gains with more families
would clearly be greater.
There are potential limitations to our study. First, we assumed the Weibull distribution,
chosen to model the penetrance function because of flexible modeling of the baseline hazard
function which includes constant, increasing or decreasing hazard functions. There might
be potential for model misspecification. Kopciuk et al. (2009) employed the generalized
log-Burr model for more flexible modeling as it includes the Weibull model or the log-logistic
model as special cases (Lawless, 2003), where the Weibull model has a monotonic functional
form of the hazard whereas the log-logistic model does not. The baseline hazard can be
also modeled semiparametrically using a step function while assuming proportional hazards.
Second, between-family heterogeneity in allele frequencies and baseline hazards can lead to
bias in parameter estimates based on the homogeneousmodels. A random effect model would
allow us to take between-family heterogeneity into account while avoiding a great number of
family-specific parameters. Finally, familial correlation is a common feature of family data due
to the unobserved genetic or environmental risk factors shared within families. We did not
explicitly model within-family dependencies, instead, we accommodated a robust variance
estimator. However, ignoring familial correlation can lead to biased estimates of the model
parameters, and so to biased disease risks (Choi et al., 2008). Relating to other work, several
authors have adopted mixed effect models for binary outcomes in family studies (Heagerty,
1999; Pfeiffer et al., 2008; Zheng et al., 2010). Shared frailty models can allow us tomodel times
to onset data from families while explicitly modeling familial correlation. We are planning to
develop such frailty models in the context of various family designs.
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